ARGX – argenx SE
argenx SEARGX
$644.48Name : argenx SE
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $39,159,246,848.00
EPSttm : -0.77
argenx SE
$644.48
0.46%$3.01Float Short %
3.34
Margin Of Safety %
Put/Call OI Ratio
0.49
EPS Next Q Diff
0.59
EPS Last/This Y
EPS This/Next Y
8.15
Price
644.52
Target Price
693.38
Analyst Recom
1.45
Performance Q
13.48
Relative Volume
0.82
Beta
0.58
Ticker: ARGX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-01-23 | ARGX | 652.2 | 0.30 | 4.63 | 6487 |
| 2025-01-24 | ARGX | 647.74 | 0.35 | 0.80 | 6810 |
| 2025-01-27 | ARGX | 649.43 | 0.36 | 0.80 | 7040 |
| 2025-01-28 | ARGX | 647.16 | 0.36 | 2.33 | 7065 |
| 2025-01-29 | ARGX | 655.19 | 0.37 | 1.00 | 7099 |
| 2025-01-30 | ARGX | 665.2 | 0.37 | 6.03 | 7099 |
| 2025-01-31 | ARGX | 656.23 | 0.40 | 2.20 | 7319 |
| 2025-02-03 | ARGX | 657.46 | 0.41 | 1.11 | 7364 |
| 2025-02-04 | ARGX | 650.57 | 0.42 | 0.24 | 7487 |
| 2025-02-05 | ARGX | 671.39 | 0.44 | 0.13 | 7645 |
| 2025-02-06 | ARGX | 658.86 | 0.43 | 6.48 | 7712 |
| 2025-02-07 | ARGX | 646.61 | 0.49 | 0.20 | 8038 |
| 2025-02-10 | ARGX | 645.71 | 0.49 | 1.00 | 8062 |
| 2025-02-11 | ARGX | 636.29 | 0.49 | 0.50 | 8084 |
| 2025-02-12 | ARGX | 647.89 | 0.50 | 0.89 | 8118 |
| 2025-02-13 | ARGX | 651.16 | 0.50 | 0.33 | 8123 |
| 2025-02-14 | ARGX | 636.87 | 0.50 | 1.38 | 8126 |
| 2025-02-18 | ARGX | 639.18 | 0.50 | 0.06 | 8145 |
| 2025-02-19 | ARGX | 640.34 | 0.50 | 0.09 | 8175 |
| 2025-02-20 | ARGX | 647.36 | 0.50 | 0.20 | 8181 |
| 2025-02-21 | ARGX | 645.2 | 0.49 | 0.25 | 8211 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-01-23 | ARGX | 652.19 | 192.8 | 549.7 | 1.74 |
| 2025-01-24 | ARGX | 647.94 | 192.8 | 548.6 | 1.74 |
| 2025-01-27 | ARGX | 649.57 | 192.8 | 544.9 | 1.74 |
| 2025-01-28 | ARGX | 647.47 | 197.5 | 535.8 | 1.74 |
| 2025-01-29 | ARGX | 655.19 | 197.5 | 545.7 | 1.74 |
| 2025-01-30 | ARGX | 665.68 | 197.5 | 547.3 | 1.74 |
| 2025-01-31 | ARGX | 655.22 | 197.5 | 536.2 | 1.74 |
| 2025-02-03 | ARGX | 657.56 | 197.5 | 531.6 | 1.74 |
| 2025-02-04 | ARGX | 651.30 | 197.5 | 532.7 | 1.74 |
| 2025-02-05 | ARGX | 671.25 | 197.5 | 553.8 | 1.74 |
| 2025-02-06 | ARGX | 658.86 | 197.5 | 536.8 | 1.74 |
| 2025-02-07 | ARGX | 646.92 | 197.5 | 529.9 | 1.74 |
| 2025-02-10 | ARGX | 646.45 | 197.5 | 534.4 | 1.74 |
| 2025-02-11 | ARGX | 636.02 | 197.5 | 525.3 | 1.74 |
| 2025-02-12 | ARGX | 648.60 | 197.5 | 546.6 | 1.74 |
| 2025-02-13 | ARGX | 651.88 | 197.5 | 545.5 | 1.74 |
| 2025-02-14 | ARGX | 639.41 | 197.5 | 537.1 | 1.74 |
| 2025-02-18 | ARGX | 638.85 | 209.5 | 547.3 | 1.74 |
| 2025-02-19 | ARGX | 640.14 | 209.5 | 542.2 | 1.74 |
| 2025-02-20 | ARGX | 648.33 | 209.5 | 544.6 | 1.74 |
| 2025-02-21 | ARGX | 644.52 | 209.5 | 544.0 | 1.74 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-01-23 | ARGX | 0.00 | 11.69 | 3.28 |
| 2025-01-24 | ARGX | 0.00 | 11.69 | 3.28 |
| 2025-01-27 | ARGX | 0.00 | 10.97 | 3.26 |
| 2025-01-28 | ARGX | 0.00 | 10.97 | 3.23 |
| 2025-01-29 | ARGX | 0.00 | 10.97 | 3.23 |
| 2025-01-30 | ARGX | 0.00 | 10.97 | 3.23 |
| 2025-01-31 | ARGX | 0.00 | 10.97 | 3.23 |
| 2025-02-03 | ARGX | 0.00 | 11.05 | 3.23 |
| 2025-02-04 | ARGX | 0.00 | 11.05 | 3.23 |
| 2025-02-05 | ARGX | 0.00 | 11.05 | 3.23 |
| 2025-02-06 | ARGX | 0.00 | 11.05 | 3.23 |
| 2025-02-07 | ARGX | 0.00 | 11.05 | 3.23 |
| 2025-02-10 | ARGX | 0.00 | 11.44 | 3.23 |
| 2025-02-11 | ARGX | 0.00 | 11.44 | 3.23 |
| 2025-02-12 | ARGX | 0.00 | 11.44 | 3.35 |
| 2025-02-13 | ARGX | 0.00 | 11.44 | 3.35 |
| 2025-02-14 | ARGX | 0.00 | 11.44 | 3.34 |
| 2025-02-18 | ARGX | 0.00 | 11.57 | 3.34 |
| 2025-02-19 | ARGX | 0.00 | 11.57 | 3.34 |
| 2025-02-20 | ARGX | 0.00 | 11.57 | 3.34 |
| 2025-02-21 | ARGX | 0.00 | 11.57 | 3.34 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.39
Avg. EPS Est. Current Quarter
1.01
Avg. EPS Est. Next Quarter
1.98
Insider Transactions
Institutional Transactions
11.57
Beta
0.58
Average Sales Estimate Current Quarter
617
Average Sales Estimate Next Quarter
709
Fair Value
Quality Score
60
Growth Score
56
Sentiment Score
79
Actual DrawDown %
5
Max Drawdown 5-Year %
-38.2
Target Price
693.38
P/E
Forward P/E
59.74
PEG
P/S
24.25
P/B
9.04
P/Free Cash Flow
EPS
-3.5
Average EPS Est. Cur. Y
1.74
EPS Next Y. (Est.)
9.9
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-12.67
Relative Volume
0.82
Return on Equity vs Sector %
-19.7
Return on Equity vs Industry %
-4.1
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.08
EBIT Estimation
544
argenx SESector: Healthcare
Industry: Biotechnology
Employees: 1148
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
stock quote shares ARGX – argenx SE Stock Price stock today
news today ARGX – argenx SE stock forecast ,stock prediction 2023 2024 2025
marketwatch ARGX – argenx SE yahoo finance google finance
stock history ARGX – argenx SE invest stock market
stock prices ARGX premarket after hours
ticker ARGX fair value insiders trading